News | Heart Valve Technology | January 06, 2017

First Pennsylvania Patient Enrolled in RECHORD Trial of Neochord DS1000 System

Nationwide trial designed to test minimally invasive treatment for mitral regurgitation

RECHORD Trial, Neochord DS1000 System, mitral regurgitation, PinnacleHealth, first Pennsylvania patient

January 6, 2017 — The RECHORD trial allows cardiovascular surgeons to replace damaged string-like tendons, called chordae, through a small incision while the heart is beating. The trial compares outcomes from this minimally invasive procedure to traditional open-heart mitral valve surgery, which requires the chest to be cracked. Specialized imaging is used to place the artificial chordae. PinnacleHealth is one of only 20 sites in the nation and the only hospital in Pennsylvania selected to participate in the trial. Up to 450 patients will be enrolled into the randomized trial.

In a healthy heart, the chordae holds heart valves in place. Over time, the tendons may stretch or break, leading to serious heart conditions, such as mitral regurgitation. Mitral valve regurgitation refers to the mitral valve not closing tightly, which does not allow blood to move through the heart or to the rest of the body as efficiently as it should. Symptoms may include feeling tired or being out of breath.

During traditional surgery to repair damaged mitral valve chordae, surgeons often have to go through the sternum and put the heart on bypass to manually place sutures. With the NeoChord System, doctors can use the device to repair mitral valve prolapse via a transapical, off-pump procedures. Placement is confirmed with imaging (echocardiogram) and then a preloaded surgical suture is deployed.

This new trial at PinnacleHealth is led by Mubashir Mumtaz, M.D., FACS, FACC, chief of cardiothoracic surgery and surgical director of structural heart, and Hemal Gada, M.D., MBA, medical director of structural heart.

"With this investigational device, we are offering new, minimally invasive mitral valve therapies to patients in our community before it is available elsewhere," said Mumtaz.

For more information: www.neochord.com

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals| February 07, 2017
GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has...
Overlay Init